Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 1081-1086

  Andrei, Graciela ^a   Sienaert, Rebecca ^a   McGuigan, Chris ^b   De Clercq, Erik ^a   Baizarini, Jan ^a   Snoeck, Robert ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINO 9 (2 PHOSPHONOMETHOXYETHYL)PURINE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 5 FURO (6 HEXYLPHENYL)DEOXYURIDINE; 5 FURO (6 PENTYLPHENYL)DEOXYURIDINE; 5 FURO (6 THIONODECYL)DEOXYURIDINE; 5 FURO 6 OCTYLDEOXYURIDINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; ADEFOVIR; ANTIVIRUS AGENT; BICYCLO COMPOUND; CF 1368; CF 1603; CF 1742; CF 1743; CIDOFOVIR; FOSCARNET; FURAN DERIVATIVE; GANCICLOVIR; PENCICLOVIR; PHOSPHONOACETIC ACID; PYRIMIDINE NUCLEOSIDE DERIVATIVE; SORIVUDINE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CROSS RESISTANCE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRAIN DIFFERENCE; VARICELLA ZOSTER VIRUS; VIRUS GENE; VIRUS INHIBITION; VIRUS MUTATION; VIRUS STRAIN;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; BROMODEOXYURIDINE; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; HERPESVIRUS 3, HUMAN; HUMANS; MICROBIAL SENSITIVITY TESTS; NUCLEOSIDES; VALINE;

EID: 14744269097     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.1081-1086.2005     Document Type: Article

References (24)

1. Andrei, G., E. De Clercq, and R. Snoeck. 2004. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? Antiviral Res. 61:181-187.
2. Andrei, G., R. Snoeck, D. Reymen, C. Liesnard, P. Goubau, J. Desmyter, and E. De Clercq. 1995. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur. J. Clin. Microbiol. Infect. Dis. 14:318-328.
3. Balzarini, J., R. Sienaert, S. Liekens, A. Van Kuilenburg, A. Carangio, R. Esnouf, E. De Clercq, and C. McGuigan. 2002. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol. Pharmacol. 61:1140-1145.
4. Balzarini, J., and C. McGuigan. 2002. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides. Biochim. Biophys. Acta 1587:287-295.
5. Balzarini, J., and C. McGuigan. 2002. Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication J. Antimicrob. Chemother. 50:5-9.
6. Breuer, J. 2003. Monitoring virus strain variation following infection with VZV: is there a need and what are the implications of introducing the Oka vaccine? Commun. Dis. Public Health 6:59-62.
7. Gross, G., H. Schöfer, S. Wassilew, K. Friese, A. Timm, R. Guthoff, H. W. Pau, J. P. Malin, P. Wutlzer, and H. W. Doerr. 2003. Herpes zoster guideline of the German Dermatology Society. J. Clin. Virol. 26:277-289.
8. Lauzurica, R., B. Bayés, C. Frias, N. Fontseré, A. Hernandez, L. Matas, A. Jimenez, J. Bonet, and R. Romero. 2003. Disseminated varicella infection in adult renal allograft recipients: role of mycophenolate mofetil. Transplant. Proc. 35:1758-1759.
9. Levin, M. J., K. M. Dahl, A. Weinberg, R. Giller, A. Patel, and P. R. Krause. 2003. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J. Infect. Dis. 188:954-959.
10. Levy, O., J. S. Orange, P. Hibberd, S. Steinberg, P. LaRussa, A. Weinberg, S. B. Wilson, A. Shaulov, G. Fleisher, R. S. Geha, F. A. Bonilla, and M. Exley. 2003. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J. Infect. Dis. 188:948-953.
11. Mattiuzzi, G. N., J. E. Cortes, M. Talpaz, J. Rèuben, M. B. Rios, J. Shan, D. Kontoyiannis, F. J. Giles, I. Raad, S. Verstovsek, A. Ferrajoli, and H. M. Kantarjian. 2003. Development of varicella-zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin. Cancer Res. 9:976-980.
12. McGuigan, C., C. J. Yarnold, G. Jones, S. Velazquez, H. Barucki, A. Brancale, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini. 1999. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. J. Med. Chem. 42:4479-4484.
13. McGuigan, C., H. Barucki, S. Blewett, A. Carangio, J. T. Erichsen, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini. 2000. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side-chain. J. Med. Chem. 43:4993-4997.
14. Pacini-Edelsteín, S. J., M. Mehra, M. E. Ament, J. H. Vargas, M. G. Martin, and S. V. McDiarmid. 2003. Varicella in pediatric liver transplant patients: a retrospective analysis of treatment and outcome. J. Pediatr. Gastroenterol. Nutr. 37:183-186.
15. Rabasseda, X. 2003. Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. Drugs Today 39:359-371.
16. Sienaert, R., L. Naesens, A. Braneale, E. De Clercq, C. McGuigan, and J. Balzarini. 2002. Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol. Pharmacol. 61:249-254.
17. Sienaert, R., L. Naesens, A. Braneale, A. Carangio, G. Andrei, R. Snoeck, A. Van Kuilenburg, E. De Clercq, C. McGuigan, and J. Balzarini. 2003. Metabolic and pharmacological characteristics of the bicyclic nucleoside analogues (BCNAs) as highly selective inhibitors of varicella-zoster virus. Nucleosides Nucleotides Nucleic Acids 22:995-997.
18. Sienaert, R., G. Andrei, R. Snoeck, E. De Clercq, C. McGuigan, and J. Balzarini. 2004. Inactivity of the bicyclic pyrimidine nucleoside analogues (BCNAs) against simian varicella virus (SVV) does not correlate with their substrate activity for SVV-encoded thymidine kinase. Biochem. Biophys. Res. Commun. 315:877-883.
19. Snoeck, R., M. Gerard, C. Sadzot-Delvaux, G. Andrei, J. Balzarini, D. Reymen, N. Ahadi, J. M. De Bruyn, J. Piette, B. Rentier, N. Clumeck, and E. De Clercq. 1994. Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient. J. Med. Virol. 42:338-347.
20. Snoeck, R., G. Andrei, and E. De Clercq. 1999. Current pharmacological approaches to the therapy of varicella zoster virus infections. A guide to treatment. Drugs 57:187-206.
21. Snoeck, R., G. Andrei, and E. De Clercq. 2000. Novel agents for the therapy of varicella-zoster virus infections. Exp. Opin. Investig. Drugs 9:1743-1751.
22. Visalli, R. J., J. Fairhurst, S. Srinivas, W. Hu, B. Feld, M. DiGrandi, K. Curran, A. Ross, J. D. Bloom, M. van Zeijl, T. R. Jones, J. O'Connel, and J. I. Cohen. 2003. Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. J. Virol. 77:2349-2358.
23. Wassilew, S. W., and P. Wutzler. on behalf of the Brivudin Herpes Zoster Study Group. 2003. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicultured study. Antiviral Res. 59:49-56.
24. Williams, S. L., C. B. Hartline, N. L. Kushner, E. A. Harden, D. J. Bidanset, Dr. J. C. Drach, L. B. Townsend, M. R. Underwood, K. K. Biron, and E. R. Kern. 2003. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47:2186-2192.